NeoGenomics Launches RaDaR ST to Capture Share in $20 Billion MRD Market

NeoGenomics has launched RaDaR ST, a tumor-informed circulating tumor DNA/ctDNA assay designed to detect molecular residual disease/MRD across various solid tumor types. The assay has a high level of sensitivity and has been validated through clinical and real-world data in several areas, including breast and head & neck cancers. The test has received Medicare approval for its initial launch indications and targets a rapidly growing MRD market estimated at over $20 billion, which NeoGenomics believes is currently less than 10% penetrated.